| Original language | English |
|---|---|
| Pages (from-to) | 936-940 |
| Number of pages | 5 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 75 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Apr 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, No. 4, 01.04.2020, p. 936-940.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Biologicals in allergic diseases and asthma
T2 - Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019
AU - Palomares, Oscar
AU - Untersmayr, Eva
AU - Gutermuth, Jan
AU - Agache, Ioana
AU - Ajeganova, Sofia
AU - Bavbek, Sevim
AU - Chan, Susan
AU - Jutel, Marek
AU - Quirce, Santiago
AU - Schmid-Grendelmeier, Peter
AU - Schmidt-Weber, Carsten
AU - Torres, María José
AU - Eiwegger, Thomas
N1 - Funding Information: Dr Chan reports nonfinancial support from Novartis and grants from Aimmune, outside the submitted work. Dr Eiwegger reports grants from DBV and Innovation fund Denmark, outside the submitted work, and he is the Co‐I or scientific lead in two investigator‐initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids. Dr Eiwegger serves as associate editor for Allergy and is in the editorial board of the IAA and the review board of JACI. Dr Gutermuth reports grants and/or personal fees from Sanofi, Novartis, Pfizer, Lilly, Abbvie, LEO, Thermo Fisher, and Janssen, outside the submitted work. Dr Jutel reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay and HAL during the conduct of the study; personal fees from Astra‐Zeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi, outside the submitted work. Dr Palomares received research grants from Inmunotek SL and Novartis and fees for giving scientific lectures from Allergy Therapeutics, Amgen, AstraZeneca, Inmunotek S.L, Novartis, Sanofi‐Genzyme, and Stallergenes. Dr Palomares has participated in advisory boards from Novartis and Sanofi‐Genezyme. Dr Schmid‐Grendelmeier reports grants and personal fees from Novartis Pharma and personal fees from F. Hoffmann‐La Roche Ltd., outside the submitted work. Prof. Dr Schmidt‐Weber reports grants from Novartis, grants and personal fees from Allergopharma, Leti Pharma, and Bencard during the conduct of the study. He also holds patents US2019083609 (A1) and WO2018234493 (A1) both issued. The rest of the authors have no conflict of interest in relation to this work.
PY - 2020/4/1
Y1 - 2020/4/1
UR - http://www.scopus.com/inward/record.url?scp=85072055243&partnerID=8YFLogxK
U2 - 10.1111/all.14024
DO - 10.1111/all.14024
M3 - Letter
C2 - 31441064
AN - SCOPUS:85072055243
SN - 0105-4538
VL - 75
SP - 936
EP - 940
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 4
ER -